A registry study in 2020 in the US showed only 40% of the patients with CKD were on ACEi/ ARBs, and smaller similar percentages (around 6%) for SGLT2i and GLP1-RA use (Nicholas, et al, Diabetes Obes Metab, 2023)
The mechanism of action includes several key effects: they stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner, suppress glucagon release (which reduces hepatic glucose production), slow gastric emptying, and act on appetite centres in the brain to promote satiety and reduce food intake
doi: 10.1002/glia.24343 41
The quest continues
If you are experiencing nausea, stick to small, frequent, and bland meals
Ideal for structured testing and extended research protocols, this bundle ensures batch consistency, secure packaging, and UK & EU supply